RECRUITING Phase 2 ClinicalTrials.gov

Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

Sponsor: University of Chicago • ClinicalTrials.gov ID: NCT06635889

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.

Interventions

Bupivacaine (Drug)
The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
Normal saline (Other)
Placebo of 50 ml of Normal Saline

Eligibility criteria

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged ≥ 18 years old. * Diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting. Exclusion Criteria: * Foley catheterization * History of allergy to bupivacaine * Antegrade ureteroscopy * Transplant or ectopic kidney * Ureteral or bladder reconstruction * Pregnancy (which is a contraindication to elective ureteroscopy) * Dialysis * Surgical complication (significant bleeding, ureteral perforation, significant urothelial damage) * Suspicion of untreated urinary tract infection * History of pelvic radiation * Neurologic disease with a diagnosis of neurogenic bladder dysfunction * History of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)

Conditions

Nephrolithiasis

Locations

The University of Chicago Medical Center — Chicago, Illinois, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment